Here are the DEF 14A proxy statements from INVO Fertility, Inc. (IVF) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow IVF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IVF filings page.
INVO Fertility, Inc. is asking stockholders to approve a wide-ranging set of proposals at its 2026 virtual annual meeting on July 23, 2026. Key items include electing five directors, ratifying WithumSmith+Brown, PC as auditor, and substantially increasing authorized common stock from 50,000,000 to 250,000,000. The company also seeks approval for issuing up to 1,893,492 shares upon exercise of Inducement Warrants, expanding its 2019 Stock Incentive Plan to 1,000,000 shares (about 20% of fully diluted stock), and pre-approving potential future equity financings that could exceed 20% of current outstanding shares at prices below recent Nasdaq trading levels. The board and management, who together beneficially own about 0.43% of voting capital, intend to vote in favor of all proposals.
INVO Fertility, Inc. is asking stockholders to vote at a virtual special meeting on January 22, 2026. The agenda includes ratifying WithumSmith+Brown, PC as independent auditor for the year ending December 31, 2025, following the dismissal of M&K CPAS, PLLC, whose 2023 and 2024 audit reports contained a statement of substantial doubt about the company’s ability to continue as a going concern.
Stockholders are asked to approve, under Nasdaq rules, issuance of up to 4,733,728 shares of common stock at an exercise price of $1.69 per share upon exercise of a warrant sold in a roughly $4,000,000 private placement, plus additional shares from adjustment events. The company also seeks to increase authorized common stock from 6,250,000 to 250,000,000 shares and to expand its 2019 Stock Incentive Plan to 1,000,000 shares, about 10% of fully diluted stock.
As of December 17, 2025, 2,386,826 common shares were outstanding, with millions more underlying warrants, options, pre-funded warrants, convertible notes, and preferred stock. The board also requests authority to adjourn the meeting to solicit more proxies if needed and recommends voting “FOR” all proposals.